Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The T-cell receptor (TCR) recognizing Juniperus monosperma allergen-derived peptides is a specialized protein complex on the surface of T-lymphocytes responsible for identifying specific antigens from one-seed juniper pollen. This recognition occurs when the TCR binds to allergen peptides, such as those from the Jun m 1 protein, presented by Major Histocompatibility Complex (MHC) class II molecules on antigen-presenting cells (Midoro-Horiuti et al., 2001). This interaction is the fundamental driver of the allergic immune response in sensitized individuals, particularly in the Southwestern United States where this species is endemic (Grier et al., 2012). Activation of these specific T-cells typically leads to a Th2-polarized cytokine environment, promoting IgE production and chronic airway inflammation (Horner et al., 1998). In clinical practice, this TCR-peptide-MHC complex is the primary target of allergen-specific immunotherapy (AIT), which seeks to desensitize the immune system (Akdis & Akdis, 2014). By repeatedly exposing the TCR to the allergen in a controlled manner, AIT aims to induce peripheral tolerance or shift the immune response toward a protective Th1 or regulatory T-cell profile (Larche et al., 2006). Consequently, this TCR is a focal point for developing next-generation peptide vaccines and diagnostic assays for seasonal respiratory allergies.
Induction of immune tolerance through T-cell anergy, deletion, or the generation of regulatory T cells (Tregs) that suppress the Th2-mediated allergic response.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T-cell receptor recognizing Juniperus monosperma allergen-derived peptides (TCR-Jun-m-1).